Cargando…

Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report

Infant‐type hemispheric glioma, a new subtype of pediatric high‐grade glioma, arises in the cerebral hemispheres. Despite better survival outcomes, the treatment of infant‐type hemispheric glioma is still facing challenges. Here, we reported a case of QKI‐ALK fusion, infant‐type hemispheric glioma w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Mingyao, Li, Shaoqun, Li, Hainan, Hu, Qingjun, Li, Juan, Zhou, Jiangfen, Ai, Ruyu, Zhen, Junjie, Zhou, Zhaoming, Wang, Lichao, Zhang, Yangqiong, Hu, Wanming, Yuan, Li, Ma, Xuejiao, Zhang, Xing, Song, Chao, Li, Zhi, Cai, Linbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187722/ https://www.ncbi.nlm.nih.gov/pubmed/37000961 http://dx.doi.org/10.1002/acn3.51766

Ejemplares similares

DIPG-26. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH CONCOMITANT TEMOZOLOMIDE ALONE IN CHILDREN WITH DIPG: A SINGLE-CENTER EXPERIENCE WITH 82 CASES
por: Lai, Mingyao, et al.
Publicado: (2020)

GCT-26. PROGNOSTIC FACTORS IN PATIENTS WITH BASAL GANGLIA GERM-CELL TUMORS: A RETROSPECTIVE ANALYSIS OF THE SINGLE CHINESE INSTITUTE EXPERIENCE FROM 2009 TO 2019
por: Hu, Qingjun, et al.
Publicado: (2020)

RADI-10. THERAPEUTIC EFFECTS OF fSRS IN 44 CASES OF BRAIN METASTASES OF NSCLC WITH A MAXIMUM DIAMETER ≥ 4CM AND ANALYSIS OF ITS PROGNOSTIC FACTORS
por: Mingyao, Lai, et al.
Publicado: (2019)

Bone metastases in an adult patient with diffuse midline glioma: a case report
por: Li, Shaoqun, et al.
Publicado: (2020)

GCT-28. RECURRENCE PATTERN AND SURVIVAL FOR RELAPSED INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMORS: A SINGLE-INSTITUTION EXPERIENCE
por: Wen, Lei, et al.
Publicado: (2020)

XRT-03. EFFICACY OF RE-IRRADIATION FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Cai, Linbo, et al.
Publicado: (2023)

HGG-14. TREATMENT AND PROGNOSTIC FACTORS FOR PEDIATRIC GLIOBLASTOMAS--THE 10 YEARS EXPERIENCE FROM ONE SINGLE CENTER
por: Li, Juan, et al.
Publicado: (2020)

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
por: Shahab, Shubin W., et al.
Publicado: (2023)

GCT-27. CLINICAL FEATURES AND PROGNOSTIC FACTORS OF NONGERMINOMATOUS GERM CELL TUMORS IN 111 CONSECUTIVE PATIENTS IN A SINGLE INSTITUTION: IMPACT OF IRRADIATION AND CHEMOTHERAPY CYCLES ON SURVIVAL
por: Wen, Lei, et al.
Publicado: (2020)

Case Report: Clinicopathological and Genetic Features of IDH-Mutant Brainstem Glioma in Adults: Report of Five Cases
por: Zhou, Jiangfen, et al.
Publicado: (2022)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
por: Wen, Lei, et al.
Publicado: (2023)

SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
por: Li, Juan, et al.
Publicado: (2023)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report
por: Li, Jie, et al.
Publicado: (2023)

SWK-04. Investigation on Anxiety and Depression of Parents of Children with Central Nervous System Tumors
por: Yang, Huajun, et al.
Publicado: (2022)

GCT-63. STEREOTACTIC RADIOSURGERY FOR RESIDUAL LESIONS OF PINEAL NON-GERMINOMATOUS GERM CELL TUMORS AFTER CONVENTIONAL RADIOTHERAPY: A RETROSPECTIVE STUDY
por: Lai, Mingyao, et al.
Publicado: (2020)

LMAP-10 RE-IRRADIATION FOR RECURRENT ADULT DIFFUSE GLIOMA
por: Zhou, Jiangfen, et al.
Publicado: (2023)

LPTO-07. CARCINOEMBRYONIC ANTIGEN OF CEREBROSPINAL FLUID PREDICT PROGNOSIS OF LEPTOMENINGEAL METASTASIS FROM NON-SMALL CELL LUNG CANCER
por: Zhen, Junjie, et al.
Publicado: (2019)

RADI-44. MANAGEMENT OF MULTIPLE BRAIN METASTASES BY STAGED SRS FOCUSING ON UTMOST RISK LESIONS
por: Zhen, Junjie, et al.
Publicado: (2019)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
por: Li, Huihui, et al.
Publicado: (2023)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
por: Chen, Wei, et al.
Publicado: (2020)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

PATH-07. Diagnostic and therapeutic value of cerebrospinal fluid biopsy in pediatric brain tumors
por: Li, Shaoqun, et al.
Publicado: (2022)

LGG-36. Analysis of BRAF-related mutations in pediatric low-grade glioma
por: Li, Shaoqun, et al.
Publicado: (2022)

OTHR-11. TUMOR RELATED IMPAIRMENTS OF NEUROCOGNITIVE FUNCTIONS IN PATIENTS WITH BRAIN METASTASES
por: Zhen, Junjie, et al.
Publicado: (2019)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
por: Hu, Jia, et al.
Publicado: (2020)

A Novel Six Autophagy-Related Genes Signature Associated With Outcomes and Immune Microenvironment in Lower-Grade Glioma
por: Lin, Tao, et al.
Publicado: (2021)

HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022)

PATH-01. Infant-Type Hemispheric Glioma: New Molecular Alterations and Precision-Medicine Treatment
por: Hu, Wanming, et al.
Publicado: (2022)

HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
por: Hu, Wanming, et al.
Publicado: (2023)

Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib
por: Nakagawa, Yoshiko, et al.
Publicado: (2022)

HGG-08. Lorlatinib for the treatment of ALK fusion positive infant high grade glioma
por: Greenwell, Alyssa, et al.
Publicado: (2022)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
por: Majeed, Umair, et al.
Publicado: (2023)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l51e6kfd2p91s8u5oufjrun3j4